Hereditary Cancer Screening Sales Executive

Myriad Genetics reported second quarter 2026 revenue of $190.7 million, down 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test. The molecular diagnostics company cited volume challenges in prenatal health and increased payer friction. The company's Cancer Care Continuum business showed momentum with 6% year-over-year test volume growth. Myriad launched Prolaris + AI for prostate cancer and expanded Precise MRD to include colorectal and renal cancers. Myriad has engaged a professional services firm to support efficiency and scalability initiatives called Ascend. The company is conducting a strategic review of its product portfolio to optimise capital allocation. The firm revised its 2026 financial guidance to reflect second quarter results and updated business assumptions for the year's second half.

Myriad Genetics (NASDAQ:MYGN) posts earnings results, misses estimates by $0.22 EPS. July 31, 2026 Key points. * Myriad Genetics reported a $0.25 per-share loss, missing estimates by $0.22, while quarterly revenue of $190.7 million fell 10.5% year over year and missed the $206.03 million consensus. * The company lowered 2026 revenue guidance to $770 million-$790 million and gross-margin guidance to 66%-67%, citing weaker prenatal volumes, reimbursement pressure, and an approximately $11 million revenue headwind. * Despite the weak results, hereditary cancer and mental-health testing volumes grew, and shares rose 6.5% to $5.37; analysts maintained a consensus "Hold" rating with a $6.50 price target. * Interested in Myriad Genetics? Here are five stocks we like better. Myriad Genetics (NASDAQ:MYGN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.22), FiscalAI reports. The company had revenue of $190.70 million for the quarter, compared to the consensus estimate of $206.03 million. Myriad Genetics had a negative net margin of 48.24% and a negative return on equity of 8.51%. Myriad Genetics's quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS. Here are the key takeaways from Myriad Genetics' conference call: * Q2 revenue fell 11% year over year to $190.7 million, as a 1% volume decline and a 9% decrease in revenue per test offset growth in hereditary cancer and mental health testing. The company also recorded an approximately $11 million revenue headwind, including a $4 million aged-receivables write-off. * Myriad lowered 2026 revenue guidance to $770 million-$790 million and gross-margin guidance to 66%-67%, citing weaker prenatal volumes and reimbursement pressure in hereditary cancer testing. Management suspended adjusted EBITDA guidance because the timing and impact of its restructuring and efficiency initiatives remain uncertain. * The Cancer Care Continuum showed solid underlying demand, with hereditary cancer volume up 8% and MyRisk volume up 10% year over year; mental-health testing volume also increased 4%. Myriad said it is addressing payer friction through improved prior-authorization, documentation, denial-management, and AI-enabled revenue-cycle workflows. * Myriad advanced several growth initiatives, including the launch of Prolaris+ AI, expanded availability of Precise MRD for breast, colorectal, and renal cancers, and the commercial launch of FirstGene prenatal screening. The company remains on track for a broader Precise MRD commercial launch in 2027 and has hired and deployed more than 100 new account executives to support future growth. * The company launched the Ascend initiative and a broader portfolio review to simplify operations, improve scalability, and focus capital on higher-value opportunities, with management expecting meaningful benefits in 2027 and beyond. Myriad ended the quarter with approximately $190 million of available liquidity but reported a $16.9 million adjusted EBITDA loss. Myriad Genetics trading up 6.5%. MYGN stock traded up $0.33 on Thursday, reaching $5.37. The company's stock had a trading volume of 2,042,605 shares, compared to its average volume of 1,566,524. The firm has a market cap of $507.20 million, a PE ratio of -1.25 and a beta of 1.64. The business has a fifty day simple moving average of $5.08 and a two-hundred day simple moving average of $4.96. Myriad Genetics has a 12-month low of $3.53 and a 12-month high of $8.59. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.19 and a current ratio of 2.40. Analyst Ratings changes. Several equities research analysts have recently issued reports on the stock. TD Cowen decreased their price target on shares of Myriad Genetics from $7.00 to $6.00 and set a "hold" rating for the company in a research note on Wednesday, May 6th. Wells Fargo & Company lowered their price target on shares of Myriad Genetics from $6.00 to $5.50 and set an "equal weight" rating on the stock in a research report on Wednesday, May 6th. Finally, Weiss Ratings raised shares of Myriad Genetics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $6.50. Discover more Stock Screener Tool Dividend Screener Tool MarketBeat Research Tools Insiders place their bets. In other news, Director Rashmi Kumar sold 15,000 shares of Myriad Genetics stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $4.46, for a total transaction of $66,900.00. Following the sale, the director owned 171,889 shares of the company's stock, valued at approximately $766,624.94. The trade was a 8.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Paul Bisaro purchased 7,500 shares of the firm's stock in a transaction that occurred on Thursday, May 14th. The stock was bought at an average cost of $3.69 per share, with a total value of $27,675.00. Following the completion of the purchase, the director owned 97,441 shares of the company's stock, valued at $359,557.29. This represents a 8.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.90% of the stock is currently owned by insiders. Institutional trading of Myriad Genetics. A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC grew its position in Myriad Genetics by 41.1% in the 4th quarter. Millennium Management LLC now owns 6,700,158 shares of the company's stock worth $41,206,000 after purchasing an additional 1,951,831 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of Myriad Genetics by 157.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company's stock valued at $17,662,000 after purchasing an additional 1,492,405 shares during the period. Kent Lake PR LLC bought a new stake in shares of Myriad Genetics during the 2nd quarter valued at about $6,638,000. Federated Hermes Inc. increased its position in shares of Myriad Genetics by 103,916.0% during the 2nd quarter. Federated Hermes Inc. now owns 1,122,333 shares of the company's stock valued at $5,960,000 after purchasing an additional 1,121,254 shares during the last quarter. Finally, State Street Corp increased its position in shares of Myriad Genetics by 19.9% during the 4th quarter. State Street Corp now owns 5,966,567 shares of the company's stock valued at $36,694,000 after purchasing an additional 990,075 shares during the last quarter. 99.02% of the stock is owned by institutional investors. About Myriad Genetics. Myriad Genetics NASDAQ: MYGN is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual's risk for various hereditary conditions and to guide personalized treatment decisions. The company's core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis(R) test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women's health, neurology and pharmacogenomics to support more informed clinical decision-making. Among its product offerings are the myRisk(R) Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel(R), a non-invasive prenatal test for assessing fetal chromosomal abnormalities. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Myriad Genetics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list. While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Myriad Genetics Q2 earnings call highlights. July 31, 2026 Key points. * Myriad Genetics' second-quarter revenue fell 11% to $190.7 million, pressured by lower test volumes, reduced reimbursement and a 9% decline in revenue per test. The company reported a $16.9 million adjusted EBITDA loss and a $0.25 adjusted loss per share. * The company cut 2026 revenue guidance to $770 million-$790 million and gross-margin guidance to 66%-67%, while suspending adjusted EBITDA guidance. Management cited prenatal weakness, hereditary-cancer reimbursement pressure and uncertainty around its efficiency initiatives. * Myriad launched reimbursement and organizational-efficiency programs, including AI-enabled revenue-cycle tools and the Ascend initiative. Product development continued with Prolaris + AI, expanded Precise MRD availability and the FirstGene prenatal screening launch, while Cancer Care and mental-health test volumes increased. * MarketBeat previews the top five stocks to own by August 1st. Myriad Genetics NASDAQ: MYGN reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on results. The company lowered its full-year revenue and gross-margin outlook and suspended adjusted EBITDA guidance amid reimbursement pressure and uncertainty surrounding a broad organizational efficiency initiative. Chief Executive Officer Sam Raha said the quarter included solid demand in the company's Cancer Care Continuum and mental health portfolios, where test volumes rose 6% and 4%, respectively. Those gains were offset by a 9% decline in prenatal testing volume. Average revenue per test was affected by approximately $11 million of lower-than-expected prior-period collections, including a $4 million write-off of aged receivables. Excluding that impact, average revenue per test declined 3% year over year, according to the company. Reimbursement pressure drives guidance cut. Myriad lowered its 2026 revenue guidance to $770 million to $790 million and projected gross margin of 66% to 67%. At the midpoint, the revenue outlook represents a $90 million reduction from its previous forecast, Chief Financial Officer Ben Wheeler said. The company cited weaker-than-expected prenatal volume, lower reimbursement levels in hereditary cancer testing, and final resolution of GeneSight accounts receivable as primary reasons for the revision. Management expects third-quarter revenue to be flat to slightly above the second quarter, followed by improvement in the fourth quarter. Myriad suspended its adjusted EBITDA guidance because the timing and financial effects of its initiatives remain uncertain. The company posted an adjusted EBITDA loss of $16.9 million in the second quarter and an adjusted loss per share of $0.25. Gross margin was 66.6%, down about 460 basis points year over year. Excluding the $11 million impact from revenue changes in estimate, gross margin would have been 68.4%, Wheeler said. The company ended the quarter with approximately $190 million in available liquidity. Discover more Stock Market Holidays AI Stocks Report Raha said payer-related revenue-cycle friction became more aggressive during the quarter, particularly for the MyRisk hereditary cancer panel. The pressure included changing prior-authorization requirements, increased medical-record requests and higher denial rates from a limited number of payers. He said the changes did not reflect shifts in medical policy or the clinical value of the tests. Management said its revised outlook assumes no recovery in average revenue per test from second-quarter levels. Wheeler said reimbursement friction is expected to remain a headwind through the remainder of 2026, although the company does not expect the magnitude of the second-quarter impact to recur. Company launches reimbursement and efficiency initiatives. Myriad is implementing revenue-cycle changes intended to improve collections and reduce administrative burdens. These efforts include enhanced coverage verification and prior-authorization workflows, integration with third-party medical-record repositories, and AI-enabled processes for document classification, denial triage, appeals and payer-response management. The company also launched a payer-by-payer market-access initiative for MyRisk, focused on policy engagement, laboratory-benefit-manager collaboration and reimbursement optimization. Separately, Myriad has begun an initiative called Ascend, supported by a professional services firm, to assess the company's organizational structure, operating model and core processes. Raha said the initiative is designed to improve efficiency, productivity and scalability, with meaningful profitability benefits expected in 2027 and beyond. Management is also conducting a portfolio review to determine the optimal allocation of capital and evaluate actions that could improve shareholder value. The company did not provide a timetable for either the Ascend initiative or the portfolio review. Cancer Care results and product progress. The Cancer Care Continuum business generated second-quarter revenue of $114.1 million, down 11% year over year. Test volume increased 6%, but average revenue per test declined 15%. Hereditary cancer testing volume increased 8%, while MyRisk volume grew 10%. Brian Donnelly, Myriad's chief commercial officer, said testing among unaffected patients delivered its strongest quarterly performance in three years. During the quarter, Myriad launched Prolaris + AI, an AI-enhanced prostate cancer test combining molecular, AI, biomarker, germline and genomic insights. Donnelly said early feedback from urologists has been positive, particularly for use in active-surveillance decisions. The company also expanded availability of its Precise MRD test for patients with breast, colorectal and renal cancers and submitted its breast-cancer indication to MolDX for a coverage determination. Myriad said it remains on track for a full commercial launch of Precise MRD in 2027. Donnelly said the company has seen a growing number of clinicians and sites use Precise MRD, including repeat orders from some providers. Myriad is continuing to improve digital ordering capabilities and customer workflows based on feedback from early users. Myriad also said it hired, trained and deployed more than 100 new account executives, primarily for the Cancer Care Continuum portfolio. The company expects those hires to begin contributing more meaningfully to volume growth in 2027 and beyond. Prenatal and mental health performance. Prenatal health revenue was $40 million, down 16% year over year, reflecting a 9% volume decline and an 8% decrease in revenue per test. Donnelly attributed the performance to factors including the timing of the sales-force expansion and competitive dynamics. The company's dedicated prenatal sales team is now fully staffed. Myriad commercially launched FirstGene during the quarter, offering simultaneous screening of carrier status, fetal single-gene conditions, fetal chromosome status and fetal RHD status in one report. Management said early customer feedback has highlighted the product's single-gene and RHD components as well as its turnaround-time characteristics. GeneSight, Myriad's mental health test, generated $36.8 million in revenue, down 3% year over year despite 4% volume growth. The business was affected by the aged-receivables write-off, although management said reimbursement trends in mental health have improved with increased payer coverage and biomarker legislation. GeneSight reached more than 40,000 ordering clinicians during the quarter, a record high for the business. About Myriad Genetics (NASDAQ:MYGN). Myriad Genetics NASDAQ: MYGN is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual's risk for various hereditary conditions and to guide personalized treatment decisions. The company's core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis(R) test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women's health, neurology and pharmacogenomics to support more informed clinical decision-making. Among its product offerings are the myRisk(R) Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel(R), a non-invasive prenatal test for assessing fetal chromosomal abnormalities. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Myriad Genetics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list. While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.